Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Tsay, Hsin-ChiehYuan, Qinggong
Balakrishnan, Asha
Kaiser, Marina
Möbus, Selina
Kozdrowska, Emilia
Farid, Marwa
Tegtmeyer, Pia-Katharina
Borst, Katharina
Vondran, Florian W R
Kalinke, Ulrich

Kispert, Andreas
Manns, Michael P

Ott, Michael
Sharma, Amar Deep
Issue Date
2018-12-22
Metadata
Show full item recordAbstract
Fibrosis, a cardinal feature of a dysfunctional liver, significantly contributes to the ever-increasing mortality due to end-stage chronic liver diseases. The crosstalk between hepatocytes and hepatic stellate cells (HSCs) plays a key role in the progression of fibrosis. Although ample efforts have been devoted to elucidate the functions of HSCs during liver fibrosis, the regulatory functions of hepatocytes remain elusive. Using an unbiased functional microRNA (miRNA) screening, we investigated the ability of hepatocytes to regulate fibrosis by fine-tuning gene expression via miRNA modulation. The in vivo functional analyses were performed by inhibiting miRNA in hepatocytes using adeno-associated virus in carbon-tetrachloride- and 3,5-di-diethoxycarbonyl-1,4-dihydrocollidine-induced liver fibrosis. Blocking miRNA-221-3p function in hepatocytes during chronic liver injury facilitated recovery of the liver and faster resolution of the deposited extracellular matrix. Furthermore, we demonstrate that reduced secretion of C-C motif chemokine ligand 2, as a result of post-transcriptional regulation of GNAI2 (G protein alpha inhibiting activity polypeptide 2) by miRNA-221-3p, mitigates liver fibrosis. Collectively, miRNA modulation in hepatocytes, an easy-to-target cell type in the liver, may serve as a potential therapeutic approach for liver fibrosis.Affiliation
HZI, Helmholtz Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7, 38124 Braunschweig Germany.Publisher
ElsevierJournal
Journal of HepatologyPubMed ID
30582979Type
ArticleISSN
1600-0641ae974a485f413a2113503eed53cd6c53
10.1016/j.jhep.2018.12.016
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
Related articles
- A lncRNA Gpr137b-ps/miR-200a-3p/CXCL14 axis modulates hepatic stellate cell (HSC) activation.
- Authors: Liao J, Zhang Z, Yuan Q, Liu Q, Kuang J, Fang Y, Hu X
- Issue date: 2021 Jan 1
- Systemic Delivery of scAAV8-Encoded MiR-29a Ameliorates Hepatic Fibrosis in Carbon Tetrachloride-Treated Mice.
- Authors: Knabel MK, Ramachandran K, Karhadkar S, Hwang HW, Creamer TJ, Chivukula RR, Sheikh F, Clark KR, Torbenson M, Montgomery RA, Cameron AM, Mendell JT, Warren DS
- Issue date: 2015
- Fibromodulin, an oxidative stress-sensitive proteoglycan, regulates the fibrogenic response to liver injury in mice.
- Authors: Mormone E, Lu Y, Ge X, Fiel MI, Nieto N
- Issue date: 2012 Mar
- Protective effect of Idelalisib on carbon tetrachloride-induced liver fibrosis via microRNA-124-3P/phosphatidylinositol-3-hydroxykinase signalling pathway.
- Authors: Li X, Li H, Zhang S, Zhang R, Li J, Wei Y, Yang C, Zhang F, Zhou H
- Issue date: 2021 Dec
- PSMP/MSMP promotes hepatic fibrosis through CCR2 and represents a novel therapeutic target.
- Authors: She S, Wu X, Zheng D, Pei X, Ma J, Sun Y, Zhou J, Nong L, Guo C, Lv P, Song Q, Zheng C, Liang W, Huang S, Li Q, Liu Z, Song Z, Li Y, Zhang Y, Kong W, You H, Xi J, Wang Y
- Issue date: 2020 Mar